Hyaluronic Acid Injectable Gel VYC-25L Is Safe and Effective for Adults Seeking Chin Enhancement to Correct Chin Retrusion: Results From a Real-world Evidence Study in China

• Published in: Aesthetic plastic surgery Vol. 49; no. 13; pp. 3545 - 3553
• Main Authors: Liang, Yimin, Zhan, Wang, Xie, Yun, Wang, Danru, Li, Qingfeng, Zhao, Grace, Chawla, Smita
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.07.2025; Springer Nature B.V
• Subjects: Adult; Aesthetics; Chin; China; Clinical medicine; Cohort Studies; Cosmetic Techniques; Data collection; Dermal Fillers - administration & dosage; Enrollments; Esthetics; Female; Follow-Up Studies; Gels; Humans; Hyaluronic acid; Hyaluronic Acid - administration & dosage; Male; Medical equipment; Medicine; Medicine & Public Health; Middle Aged; Original; Original Articles; Otorhinolaryngology; Patient Satisfaction - statistics & numerical data; Plastic Surgery; Prospective Studies; Retrospective Studies; Risk Assessment; Three dimensional imaging; Treatment Outcome; Young Adult; China; Esthetics; Jaw; Chin; Injection; Hyaluronic acid; Asian
• ISSN: 0364-216X; 1432-5241; 1432-5241
• DOI: 10.1007/s00266-024-04572-3

Background Chinese individuals may seek chin enhancement to address esthetic perceptions regarding chin retrusion. Because studies of the injectable hyaluronic acid gel VYC-25L (Allergan Aesthetics, an AbbVie Company, Irvine, CA) contained few Asian subjects and none from China, its effects on chin retrusion in Chinese individuals are unclear. This 12-month, real-world evidence study evaluated the safety and effectiveness of VYC-25L for chin enhancement in Chinese adults. Methods At Hainan Bo’ao Super Hospital, 2 cohorts of prospectively and retrospectively enrolled adults received VYC-25L treatment (maximum 4 mL). Cohort 1 only underwent 3D imaging before and after treatment for digital analysis. The primary effectiveness measure was mean change from baseline in glabella–subnasale–pogonion (G–Sn–Pog) angle at month 3 based on 3D facial images. Both cohorts completed the Global Aesthetic Improvement Scale (GAIS; subjects and investigators) and a satisfaction questionnaire (subjects). Injection site response (ISR) and adverse events were recorded. Results Of 90 subjects enrolled (cohort 1, n=36; cohort 2, n=54), 89 completed the study. Mean change from baseline in G–Sn–Pog angle at month 3 was 3.19 degrees (95% CI, 2.55–3.83; P < 0.001 vs 0), with improvement maintained through 12 months. Month 3 “improved”/“much improved” GAIS responder frequencies were 94.3% (investigators) and 97.1% (subjects); 91.5% of subjects were “satisfied”/“very satisfied” with treatment at month 3. Most (>70%) ISRs were mild or moderate in severity. Four treatment-related adverse events occurred (all mild). Conclusion VYC-25L was safe and effective for enhancement of the chin and jaw in Chinese adults. Level of Evidence III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .